Publications by authors named "Peter Varunok"

Claim this Profile
E
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Eric Lawitz, Mihály Makara, Ulus Salih Akarca, Paul J Thuluvath, Liliana Lucia Preotescu, Peter Varunok

Gastroenterology· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
Jacob Lalezari, J Greg Sullivan, Peter Varunok, Edward Galen, Kris V Kowdley

J Hepatol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
David R Nelson, James N Cooper, Jacob P Lalezari, Eric Lawitz, Paul J Pockros, Peter Varunok

Hepatology· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Stefan Zeuzem, Ira M Jacobson, Tolga Baykal, Rui T Marinho, Fred Poordad, Peter Varunok

N Engl J Med· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device.
Peter Varunok, Eric Lawitz, Kimberly L Beavers, Gary Matusow, Ruby Leong

Patient Prefer Adherence· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis